An investigation into the formation of Tebufenozide (cas 112410-23-8)'s toxic aromatic amine metabolites in human in vitro hepatic microsomes
-
Add time:07/27/2019 Source:sciencedirect.com
Tebufenozide is a nonsteroid ecdysone agonist that causes premature and incomplete molting in Lepidoptera. Studies conducted so far have shown the low toxicity of tebufenozide in mammals, birds and invertebrates. Tebufenozide potential metabolites such as aromatic amines are known to induce methemoglobinemia disorder in humans, most likely by the formation of N-hydroxy metabolites; therefore, the aim of this research is to investigate the formation of the potential toxic N-hydroxy derivatives in pooled human hepatic microsomal fractions. Analyses of metabolites by high performance liquid chromatography equipped by a time-of-flight detector (HPLC/TOF) indicated the formation of a hydroxylated metabolite (exact mass = 369; retention time: 6.65 min) and two de-dimethylethyl metabolites (exact masses = 313; retention times: 5.76 and 6.22 min). Hydroxylated tebufenozide metabolite resulted from hydroxylation at either the 3 or 5 position of the dimethylbenzoic acid moiety to form either 3-hydroxymethyl-5-methylbenzoic acid 1-(1,1-dimethylethyl)-2-(4-ethylbenzoyl) or 3-methyl-5-hydroxymethylbenzoic acid 1-(1,1-dimethylethyl)-2-(4-ethylbenzoyl), respectively. The two de-dimethylethyl-tebufenozide derivatives were 3,5-dimethylbenzoic acid-2-(4-hydroxyethylbenzoyl) and 3-hydroxymethyl-5-methylbenzoic acid-2-(4-ethylbenzoyl) or 3-methyl-5-hydroxymethylbenzoic acid-2-(4-ethylbenzoyl). Generally the metabolite formation rates increased with incubation time. The rate of hydroxylation of the dimethylbenzoic acid moiety was approximately 12 times higher than the hydroxylation of the ethylbenzoyl moiety. Tebufenozide does not appear to produce the toxic aromatic amine metabolites in human in vitro hepatic microsomes. This suggests that the fate of tebufenozide in humans is a process of detoxification rather than activation.
We also recommend Trading Suppliers and Manufacturers of Tebufenozide (cas 112410-23-8). Pls Click Website Link as below: cas 112410-23-8 suppliers
Prev:Identification and in silico prediction of metabolites of the model compound, Tebufenozide (cas 112410-23-8) by human CYP3A4 and CYP2C19
Next:Biochemical mechanisms conferring cross-resistance between Tebufenozide (cas 112410-23-8) and abamectin in Plutella xylostella) - 【Back】【Close 】【Print】【Add to favorite 】
- Related Information
- Biochemical mechanisms conferring cross-resistance between Tebufenozide (cas 112410-23-8) and abamectin in Plutella xylostella07/28/2019
- Identification and in silico prediction of metabolites of the model compound, Tebufenozide (cas 112410-23-8) by human CYP3A4 and CYP2C1907/26/2019
- Tebufenozide (cas 112410-23-8) disrupts ovarian development and function in silkmoths07/25/2019
- Dissipation and metabolism of Tebufenozide (cas 112410-23-8) in cabbage and soil under open field conditions in South China07/24/2019
- Tebufenozide (cas 112410-23-8) induces G1/S cell cycle arrest and apoptosis in human cells07/23/2019
- Residue analysis and dietary exposure risk assessment of Tebufenozide (cas 112410-23-8) in stem lettuce (Lactuca sativa L. var. angustana Irish)07/22/2019
- Cytotoxic effects of Tebufenozide (cas 112410-23-8) in vitro bioassays07/20/2019
- Toxicological and morphological effects of Tebufenozide (cas 112410-23-8) on Anticarsia gemmatalis (Lepidoptera: Noctuidae) larvae07/21/2019
- Molecular mechanisms conferring asymmetrical cross-resistance between Tebufenozide (cas 112410-23-8) and abamectin in Plutella xylostella07/19/2019


